NCT01832974View on ClinicalTrials.gov

Possible New Therapy for Advanced Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

September 30, 2014

Conditions
Adrenocortical Carcinoma
Interventions
DRUG

IL-13-PE

IL-13-PE intravenous infusion

Trial Locations (1)

20892

National Cancer Institute at the National Institutes of Health, Bethesda

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

INSYS Therapeutics Inc

INDUSTRY

NCT01832974 - Possible New Therapy for Advanced Cancer | Biotech Hunter | Biotech Hunter